What if you could test a drug candidate on people before clinical trials? What if, instead of mice, a human computer model could be the first “lab rat” to determine the efficacy of a molecule, or to provide insight into a potential drug target?
Hear from our CEO, Colin Hill, as he unveils the transformative potential of Gemini Digital Twins in drug development, shedding light on our latest partnership with Charles River Labs in drug discovery and the strategic partnership agreement, focused on the development of a patient-derived xenograft (PDX) Digital Twin to predict the best tumor models for in vivo oncology research.
Discover how these AI-driven replicas of human biology are reshaping the landscape, accelerating drug discovery, and enhancing precision medicine.
Full article on Eureka, the science blog of Charles River, here.